[Video] Cue Biopharma Q&A Session With Dr. D.J. Verret
In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data
![[CUE] “That Data Is Amazing!” So Why Is The Stock Down?](https://disruptivetr.com/wp-content/uploads/2022/01/DTR.CUE_.Data_.jpg)
[CUE] “That Data Is Amazing!” So Why Is The Stock Down?
Here’s a full rundown on the important takeaways from CUE’s conference call and my thoughts on the recent trading activity…
![[Video] What To Expect From CUE This Afternoon](https://disruptivetr.com/wp-content/uploads/2022/01/DTR.CUE_.Jan_.26.jpg)
[Video] What To Expect From CUE This Afternoon
Like expectant parents, everyone’s wondering what will be revealed on today’s update call. Here are my reasonable expectations…
CUE Q1 2019 Key Takeaways: Despite IR Misstep, On Track For Data-Rich, “Transformational” Year
Five key takeaways from Cue Biopharma’s Q1 2019 report, including the list of catalysts management believes will result in 2019 being a “transformational” year…
CUE: Major Milestone Met On Path to Immunotherapy Market Disruption
Here are three reasons why today’s FDA approval to enter the clinic with CUE-101 for HPV-associated cancers is significant, including two not so obvious reasons. Plus, a list of catalysts for 2019…